-
-
-
-
-
-
-
Vertex Presents New Data on CASGEVY®, Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions
-
-
-
-
-
-
-
Vertex Announces CASGEVY® Reimbursement Agreement for the Treatment of Transfusion-Dependent Beta Thalassemia and Sickle Cell Disease in Italy
-
-
-
-
-
-
-
Vertex (VRTX) PT Lowered to $420 at RBC Capital
-
-
-
-
-
-
-
Goldman lists stocks offering stability and visibility amid global uncertainty
-
-
-
-
-
-
-
Vertex to Announce Fourth Quarter and Full Year 2024 Financial Results on February 10
-
-
-
-
-
-
-
Vertex (VRTX) PT Raised to $550 at Oppenheimer
-
-
-
-
-
-
-
Alpine Immune Sciences Reports First Quarter 2024 Financial Results
-
1,168,522 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

